DPP4 and Stroke: In this regard, it should be noted that, more recently, the observational cohort study in 11 countries, EMPagliflozin comparative effectiveness and Safety (EMPRISE), was published, which even suggests that empagliflozin may be associated with an 18% reduction in the risk of stroke compared with dipeptidyl peptidase 4 inhibitors (DPP4is) [64].